Breast cancer (BC) is the most common malignant tumor and the leading cause of cancer-related death among women. BC-related deaths account for 6.6% of all cancer-related deaths. The most common therapeutic approaches are surgery, radiation treatment, targeted endocrine therapy, and chemotherapy. Due to tumor heterogeneity and multidrug resistance, the overall survival of BC patients still remains suboptimal. Furthermore, metastasis of BC is one of the main reasons for poor survival in patients. Of the deaths caused by BC, over 90% are attributed to metastasis-related complications.
Many studies have increased our understanding of the causes of BC and have helped to develop new therapeutic options for this disease. This has resulted in the definition of multiple molecular pathways that contribute to the development of BC. However, the underlying mechanisms that dictate the progression and metastasis of BC are complex and influenced by many factors. To improve survival for BC patients, it is vital to further our understanding of the molecular mechanisms associated with BC to allow us to identify new molecular targets and therapeutic options.
This Research Topic aims to elucidate the molecular mechanisms associated with BC progression and metastasis. We welcome papers on the following topics:
- Key signalling pathways in BC and their potential as therapeutic targets
- Epithelial-mesenchymal transition in BC progression and metastasis
- The role of LncRNAs in BC progression and metastasis
- Interplay between cancer cells and tumor microenvironment in BC progression and metastasis
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Breast cancer (BC) is the most common malignant tumor and the leading cause of cancer-related death among women. BC-related deaths account for 6.6% of all cancer-related deaths. The most common therapeutic approaches are surgery, radiation treatment, targeted endocrine therapy, and chemotherapy. Due to tumor heterogeneity and multidrug resistance, the overall survival of BC patients still remains suboptimal. Furthermore, metastasis of BC is one of the main reasons for poor survival in patients. Of the deaths caused by BC, over 90% are attributed to metastasis-related complications.
Many studies have increased our understanding of the causes of BC and have helped to develop new therapeutic options for this disease. This has resulted in the definition of multiple molecular pathways that contribute to the development of BC. However, the underlying mechanisms that dictate the progression and metastasis of BC are complex and influenced by many factors. To improve survival for BC patients, it is vital to further our understanding of the molecular mechanisms associated with BC to allow us to identify new molecular targets and therapeutic options.
This Research Topic aims to elucidate the molecular mechanisms associated with BC progression and metastasis. We welcome papers on the following topics:
- Key signalling pathways in BC and their potential as therapeutic targets
- Epithelial-mesenchymal transition in BC progression and metastasis
- The role of LncRNAs in BC progression and metastasis
- Interplay between cancer cells and tumor microenvironment in BC progression and metastasis
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
